Kremer Alton B 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Oct 3, 2007
Insider Transaction Report
Form 4
Kremer Alton B
VP, Clinical Research
Transactions
- Exercise/Conversion
ESPP (right to buy)
2007-10-01−2,328→ 0 totalExercise: $19.03From: 2007-10-01Exp: 2007-10-02→ Common Stock (2,328 underlying) - Tax Payment
Common Stock
2007-10-01$22.39/sh−2,119$47,444→ 29,685 total - Award
ESPP (right to buy)
2007-10-01+735→ 735 totalExercise: $22.11From: 2008-04-01Exp: 2008-04-01→ Common Stock (735 underlying) - Exercise/Conversion
Common Stock
2007-10-01$19.03/sh+2,328$44,302→ 31,804 total
Footnotes (4)
- [F1]Acquired upon the complete exercise of a grant under the Non-Qualified Employee Stock Purchase Plan, which grant was previously reported at the start of a six month option term, to acquire common stock up to an option amount which is 25% of the optionee's quarterly salary less $6,250, at a purchase price equal to the lower of 100% of the market value on the date of grant or 85% of the market value on the date of exercise.
- [F2]Includes shares of common stock acquired from the non-reportable exercise under a Qualified Employee Stock Purchase Plan.
- [F3]Granted under the Company's Non-Qualified Employeee Stock Purchase Plan.
- [F4]The option was granted on the first day of the option term and previously reported as a right to purchase shares of the Company's common stock at an exercise price equal to the market value on the date of grant. In accordance with the Non-Qualified Employee Stock Purchase Plan, the option is ultimately exercisable for an exercise price which is the lower of 100% of the market value on the grant date or 85% of the market value on the day prior to the exercise date. The number of shares exercised is based on the option amount divided by the lower of 100% of the market value on the grant date or 85% of the market value on the day prior to the exercise date.